The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease
Abstract
It is unclear whether physiologic hemoglobin targets lead to cardiac benefit in incident hemodialysis patients without symptomatic heart disease and left ventricular dilation. In this randomized, double-blind study, lower (9.5 to 11.5 g/dl) and higher (13.5 to 14.5 g/dl) hemoglobin targets were generated with epoetin alpha over 24 wk and maintained for an additional 72 wk. Major eligibility criteria included recent hemodialysis initiation and absence of symptomatic cardiac disease and left ventricular dilation. The primary outcome measure was left ventricular volume index (LVVI). The study enrolled 596 patients. Mean age, duration of dialysis therapy, baseline predialysis hemoglobin, and LVVI were 50.8 yr, 0.8 yr, 11.0 g/dl, and 69 ml/m2, respectively; 18% had diabetic nephropathy. Mean hemoglobin levels in the higher and lower target groups were 13.3 and 10.9 g/dl, respectively, at 24 wk. Percentage changes in LVVI between baseline and last value were similar (7.6% in the higher and 8.3% in the lower target group) as were the changes in left ventricular mass index (16.8 versus 14.2%). For the secondary outcomes, the only between-group difference was an improved SF-36 Vitality score in the higher versus the lower target group (1.21 versus -2.31; P = 0.036). Overall adverse event rates were similar in both target groups; higher (P < 0.05) rates of skeletal pain, surgery, and dizziness were seen in the lower target group, and headache and cerebrovascular events were seen in the higher target group. Normalization of hemoglobin in incident hemodialysis patients does not have a beneficial effect on cardiac structure, compared with partial correction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sahn, D. J., DeMaria, A., Kisslo, J., & Weyman, A. (1978) · Circulation · doi:10.1161/01.cir.58.6.1072 · Cited by 7,430
The RAND-36 measure of health-related quality of life
Hays, R. D., & Morales, L. S. (2001) · Annals of Medicine · doi:10.3109/07853890109002089 · Cited by 1,460
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Martin, C. J., Murray, D. C., & Barre, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.22 · Cited by 1,299
Self-citationDevelopment of the Kidney Disease Quality of Life (KDQOLTM) Instrument
Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., & Carter, W. B. (1994) · Quality of Life Research · doi:10.1007/bf00451725 · Cited by 1,193
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barre, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 784
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90130-4 · Cited by 769
Self-citationLeft Ventricular Volumes and Ejection Fraction by Echocardiography
POMBO, J. F., TROY, B. L., & RUSSELL, R. O. (1971) · Circulation · doi:10.1161/01.cir.43.4.480 · Cited by 647
Hematocrit Level and Associated Mortality in Hemodialysis Patients
MA, J. Z., EBBEN, J., XIA, H., & COLLINS, A. J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103610 · Cited by 577
Devereux, R. B. (1987) · Hypertension · doi:10.1161/01.hyp.9.2_pt_2.ii19 · Cited by 550
Breast cancer trial with erythropoietin terminated unexpectedly
Leyland-Jones, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01163-x · Cited by 474
Cited by
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Self-citationLevey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Babitt, J. L., & Lin, H. Y. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111078 · Cited by 1,041
Metadata
- Authors
- Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-07
- Volume
- 16
- Issue
- 7
- Pages
- 2180-2189
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2103517401
- Cited by
- 373
- References
- 26
- FWCI
- 21.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease. https://app.cochat.ai/papers/10.1681/asn.2004121039
- The paper
- Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D. (2005). Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2004121039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
